Cosmo Pharmaceuticals

What Cosmo Pharmaceuticals does

Cosmo Pharmaceuticals N.V. is a publicly traded specialty pharmaceutical and MedTech AI company headquartered in Dublin, Ireland, and listed on the SIX Swiss Exchange (COPN) and OTCMKTS (CMOPF). Founded in 1996, the company operates four strategic divisions under its Vision 2030 strategy: MedTech AI, Dermatology, Gastroenterology, and CDMO (Contract Development and Manufacturing). Its flagship product is GI Genius™, a real-time AI-powered colonoscopy system that provides computer-vision-based detection of colorectal lesions during procedures, built on NVIDIA accelerated computing infrastructure and distributed globally through Medtronic.

The company's pharmaceutical portfolio centers on clascoterone, a first-in-class topical androgen receptor inhibitor deployed as Winlevi® for acne vulgaris (approved by the European Commission across 20 European markets in late 2025) and as Clascoterone 5% topical solution for male androgenetic alopecia (Phase III positive, US FDA filing planned for early 2027). Additional products include Cerebro, an AI-powered EGD guide that received EU MDR certification in May 2025, and Aemcolo (Rifamycin SV MMX 200 mg) for traveler's diarrhea, distributed in partnership with Adalvo Ltd.

Cosmo's business model blends direct enterprise sales and recurring service revenue for GI Genius™ with licensing royalties and partnership-driven commercialization for its pharmaceutical products. FY2025 total revenue was €104.2M with EBITDA of €9.5M; the company is debt-free with €128.3M in cash and liquidity, and approved a €2.10 per share dividend at the 2026 AGM. The company serves hospital systems, gastroenterology departments, and dermatology prescribers across Europe and North America, with manufacturing operations in Italy.

Name

Cosmo Pharmaceuticals

Legal name

Cosmo Pharmaceuticals N.V.

Website

https://cosmopharma.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

Cosmo Pharmaceuticals is a Dublin-headquartered specialty pharma and MedTech AI company developing AI-powered colonoscopy (GI Genius™), AI endoscopy guidance (Cerebro), and topical clascoterone products for acne (Winlevi®) and male hair loss, serving hospital systems and dermatology prescribers across Europe and North America.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals and AI Medical Devices

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Surgical and Medical Instrument Manufacturing (339112)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Specialty pharmaceuticals
• AI medical devices
• Gastroenterology treatments
• Dermatology therapeutics
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. GI Genius™ and MedTech AI Platform: Recurring revenue from the GI Genius™ AI colonoscopy system, including AI module upgrades, service agreements, and related support services. The company reports growth in recurring revenues from this platform as a key financial driver.
2. Winlevi® (Dermatology) Licensing and Royalties: Revenue from licensing Winlevi® to commercial partners, including Glenmark Specialty SA for European markets (15+ countries approved). Cosmo receives licensing royalties on net sales of Winlevi® across approved territories.
3. Clascoterone Hair Loss Treatment (pipeline): Post-approval revenue anticipated from Clascoterone 5% topical solution for male androgenetic alopecia. FDA filing is planned for early 2027 following positive Phase III results. Revenue model will include prescription sales through pharmacy channels.
4. CDMO (Contract Development and Manufacturing): Contract manufacturing services offered through the company's manufacturing capabilities, supporting the company's fourth strategic growth pillar alongside MedTech AI, dermatology, and gastroenterology.
5. Rifamycin SV MMX / Aemcolo: Revenue from the sale of Rifamycin SV MMX 200 mg (Aemcolo) for traveler's diarrhea, co-launched with Adalvo Ltd. in September 2023.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Cosmo Pharmaceuticals develops and commercializes specialty pharmaceutical products and AI-powered medical devices across four divisions: MedTech AI (GI Genius™ real-time colonoscopy AI system and Cerebro EGD guide), Dermatology (Winlevi®/clascoterone for acne and a clascoterone 5% solution for male androgenetic alopecia), Gastroenterology (Rifamycin SV MMX/Aemcolo for traveler's diarrhea, plus AI-based Barrett's esophagus detection), and CDMO (Contract Development and Manufacturing Organization) services delivered from its Italian manufacturing facility.

Product overview

Cosmo Pharmaceuticals operates as a life sciences company with four strategic divisions: MedTech AI, Dermatology, Gastroenterology, and CDMO. The core product portfolio centers on GI Genius™, an AI-powered colonoscopy system providing real-time detection during medical procedures; Winlevi®, an approved acne treatment; and Clascoterone 5% topical solution for male hair loss in Phase III development. The company is expanding its AI capabilities through Cerebro (EGD guide) and Barrett's esophagus detection systems. CDMO services support manufacturing capabilities across the portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• GI Genius: AI-powered colonoscopy system for real-time clinical environments with detection, decision support, and workflow optimization.
• Winlevi
• Breezula
• Cerebro

Products and services

• GI Genius™ AI-powered colonoscopy system that provides real-time detection, decision support, and workflow optimization during colorectal cancer screening procedures. Built on NVIDIA accelerated computing and distributed globally in part through Medtronic. Targets hospital systems and gastroenterology departments.
• Winlevi® (Clascoterone 1% cream) Clascoterone-based prescription topical treatment for acne vulgaris in adolescents and adults, commercialized in Europe via Glenmark Specialty SA.
• Clascoterone 5% Topical Solution (male androgenetic alopecia) Topical androgen receptor inhibitor for male androgenetic alopecia; Phase III program enrolled 1,465 subjects across 51 centers in US and Europe — the largest topical male AGA Phase III program on record.
• Cerebro AI-powered endoscopy guide for esophagogastroduodenoscopy (EGD) procedures; received EU MDR Class IIa certification in May 2025 for upper gastrointestinal procedure guidance.
• Rifamycin SV MMX 200 mg (Aemcolo) Antibiotic designed to target the colon directly with reduced impact on gut bacteria, indicated for traveler's diarrhea; distributed through Adalvo Ltd.
• GI Genius™ Barrett's Esophagus AI Detection System AI-based computer-aided detection system under development for identifying early neoplasia in Barrett's esophagus, expanding the GI Genius™ platform beyond colorectal cancer into upper GI indications.
• CDMO (Contract Development and Manufacturing) Services Contract pharmaceutical development and manufacturing services delivered from Cosmo's Italian manufacturing facility for pharmaceutical and biotech clients.

Quantifiable outcome

• 539% and 168% improvement in target-area hair count vs placebo at 12 months for Clascoterone 5%
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Amsterdam UMC and Eindhoven University of TechnologycoreStrategic or Co-development Partner · 5 March 2026Cosmo entered a strategic R&D collaboration with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an AI-based computer-aided detection system for identifying early neoplasia in Barrett's esophagus. The collaboration aims to create one of the most comprehensive curated datasets for Barrett's esophagus AI development, combining clinical expertise, imaging research, and engineering capabilities. Cosmo leads industrialization and regulatory pathway submissions in Europe and the United States, expanding the GI Genius™ platform into upper GI indications.
• Glenmark Specialty SAcoreChannel Partner/ Reseller/ Distributor · 21 October 2025Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty SA, commercializes Winlevi® (clascoterone) across 20 European markets for treating acne vulgaris in adolescents and adults. This is Glenmark's first new chemical entity launch in Europe. Glenmark's subsidiary Infectopharm launched Winlevi® in Germany and Austria, with further European market launches underway.
• Adalvo Ltd.minorChannel Partner/ Reseller/ Distributor · 1 September 2023Malta-based Adalvo Ltd. partnered with Cosmo to jointly launch Rifamycin SV MMX 200 mg (Aemcolo), an antibiotic for traveler's diarrhea targeting the colon directly with reduced impact on gut bacteria. Launched in September 2023.
• MedtroniccoreGTM or Marketing PartnerMedtronic distributes the GI Genius™ AI colonoscopy system as part of its AI ecosystem strategy. Medtronic's AI strategy analysis (Klover) references Cosmo as a key partnership in Medtronic's broader AI platform strategy, leveraging GI Genius for integration into Medtronic's GI AI Access ecosystem alongside NVIDIA and other partners.
• NVIDIAcoreTechnology or IntegrationCosmo leverages NVIDIA's accelerated computing technologies to develop AI platforms that assist physicians during medical procedures. Cosmo presented at NVIDIA GTC 2026 showcasing its engineering of medical-grade platforms for real-time AI deployment, including GI Genius™ which uses NVIDIA technology for real-time clinical environments.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Bausch Health: Diversified specialty pharma holding company with material exposure to both gastroenterology (Salix) and dermatology (Ortho Dermatologics) — comparable in therapeutic mix to Cosmo's gastroenterology and dermatology pillars, though at significantly greater scale and breadth.
• Olympus Corporation: Global endoscopy device incumbent with rapidly expanding AI-augmented endoscopy offerings and large installed base in hospital systems — broad incumbent in the same GI endoscopy + AI category where Cosmo's GI Genius™ competes for hospital procurement budgets.

Direct peers

• Almirall: European-listed specialty pharmaceutical company with a concentrated dermatology franchise spanning acne, actinic keratosis, and atopic dermatitis — a close structural analogue to Cosmo's dermatology focus and EU commercialization orientation.
• Galderma: Global dermatology specialty pharmaceutical company focused on acne, aesthetics, and skin health — directly comparable to Cosmo's dermatology franchise anchored by Winlevi® and the Clascoterone pipeline for acne and androgenetic alopecia.
• Salix Pharmaceuticals: US specialty GI pharma franchise owned by Bausch Health, focused on colonic and gastrointestinal disease therapeutics — directly comparable to Cosmo's gastroenterology portfolio including Rifamycin SV MMX (Aemcolo) and its broader GI therapeutic focus.
• Arcutis Biotherapeutics: US-based late-stage dermatology specialty pharma developing novel topical therapies for inflammatory skin conditions including seborrheic dermatitis and atopic dermatitis — comparable in size, single-therapeutic-area focus, and reliance on US FDA approval catalysts.
• Dermavant Sciences: Late-stage dermatology specialty pharma (now part of Organon) that developed novel topical therapies including a TAMA for atopic dermatitis — a structurally similar specialty dermatology peer focused on novel topical mechanism of action drugs, comparable to Cosmo's clascoterone strategy.
• Ferring Pharmaceuticals: Private global specialty pharma with a strong gastroenterology and reproductive health franchise — directly comparable to Cosmo's GI therapeutic focus and CDMO/contract manufacturing presence, with similar mid-sized specialty pharma profile.

Emerging players

• Iterative Health: Emerging MedTech AI company developing AI-enabled gastroenterology tools, including AI colonoscopy — a direct emerging competitor in the same clinical AI space as Cosmo's GI Genius™ platform.
• Sol-Gel Technologies: Smaller dermatology specialty pharma developing topical therapies for acne and rare skin diseases — comparable in therapeutic focus (topical dermatology) and scale to Cosmo's dermatology franchise, representing a partial-overlap emerging peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cosmo_pharma
• YouTubeyoutube.com/@Cosmo-BuildingHealthConfidence
• LinkedInlinkedin.com/company/3234407

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cosmo Pharmaceuticals